Chinese language medtech Baird Clinical to head public thru SPAC merger (XFIN)
ClaudioVentrella/iStock by the use of Getty Pictures
Chinese language medtech Baird Clinical (BDMD) plans to head public thru a merger with SPAC ExcelFin Acquisition Corp. (NASDAQ:XFIN).
The deal pegs the undertaking worth of the blended corporate at $370M, with stocks anticipated to business on Nasdaq underneath the emblem BDMD.
Headquartered in Guangzhou, Baird is a number one developer and supplier of microwave ablation units in China. The corporate is predicted to document 2023 web source of revenue of $18M on earnings of $45M. For 2022, Baird reported earnings of $35M, in step with the corporations.
Extra on healthcare SPACs:
AUM Biosciences terminates merger with SPAC Mountain Crest V
SPAC Phoenix Biotech to merge with immunology drug developer CERo
